Media ReleasesImmutep

View All Immutep News

Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast

Chief Medical Officer Dr. Frederic Triebel to Present at the 3rd Annual Advances in Immuno-Oncology Congress

SYDNEY, AUSTRALIA – May 17, 2018 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, advises that its Chief Medical Officer and Chief Scientific Officer, Dr. Fre´de´ric Triebel, will present interim results from the three initial patient cohorts of its ongoing TACTI-mel Phase I clinical trial in a global webcast and Q&A. The webcast will also include an update on the Company’s clinical immuno-oncology combination program.

For further information please download PDF attached:
Download this document